GB1275

Developed for: castration-resistant prostate carcinoma · colorectal cancer · esophageal adenocarcinoma · esophageal squamous cell carcinoma · gastric adenocarcinoma · gastroesophageal junction adenocarcinoma · head and neck squamous cell carcinoma · hepatocellular carcinoma
+6 more
· non-small cell lung carcinoma · pancreatic adenocarcinoma · renal cell carcinoma · small cell lung carcinoma · triple-negative breast carcinoma · urothelial carcinoma
Investigated by: Gossamer Bio, Inc. · Merck Sharp & Dohme LLC

today NCT04060342 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04060342	Aug 2019 → Apr 2022	castration-resistant prostate carcinoma, colorectal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma +10	Gossamer Bio, Inc.	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	GB1275	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04060342 ↗
Route	Oral	“GB1275 oral administration; twice per day (BID)” NCT04060342 ↗